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Antibacterial activity of local anaesthetic
agents
J Antimicroh Chemother 1994; 33: 661
Sir,
In their excellent overview on antibacterial
activity of non-antibiotic drugs Cederlund &
Mardh (1993) did not mention local anaes-
thetics such as tetracaine, dibucaine, procaine
and lidocaine, which have potent antimicrobial
activity as detected by effects on cell growth
rates and viability of Escherichia coli and
Candida albicans in vitro. The effects of lido-
caine on bacterial growth in a chemically
defined medium has been compared with that
of antibacterial agents such as ampicillin,
chloramphenicol, puromycin and cationic
surface-active agents (Abanzukwe, Fazley
Bazaz & Salt, 1991). Although local anaes-
thetics are 1000 fold less toxic to both pro-
caryotic and eucaryotic cells than active
quaternary ammonium disinfectants, their
antibacterial activity could be of concern for
the yield of broncho-alveolar lavage (BAL)
fluid bacteriology. Bronchoscopists instill
10-15 mL 2% lidocaine into the bronchial tree
before performing BAL. If allowed to mix with
50 mL BAL fluid, 200-300 mg of lidocaine
would attain a concentration of
4000-6000 mg/L, enough to induce membrane
damage in bacterial organisms and possibly
compromise their growth in culture.
Fortunately removal of the local anaesthetic
permits bacterial cell recovery and growth.
There is, however, no study comparing the
bacteriological yield of BAL with and without
the use of local anaesthetics.
FRANCO de'CLARI
Intensive Care Unit,
Ospedate Civico,
6900 Lugano
Via Tesserete 46.
Switzerland
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Sir,
Mycobacteria of the Mycobacterium avium
complex (MAC) are significant human and
animal pathogens. Treatment options have
been limited because of resistance to most
antimicrobial agents. Such intrinsic resistance
has been attributed to the characteristics of the
cell wall structure of MAC, but the precise
molecular bases have not been elucidated. In
contrast, significant progress has been made in
the understanding, at molecular level, of resist-
ance to the main antituberculous drugs in
Mycobacterium tuberculosis: resistance to
isoniazid has been mapped to the gene for the
catalase-peroxidase (Zhang et al., 1992),
rifampicin to the RNA polymerase subunit ji
(Telenti et al., 1993a), fluoroquinolones to the
gyrase A (TakifT, H., Salazar, L., Guerrero, C ,
Philipp, W., Huang, W. M., Kreiswirth, B. et
al., unpublished observations), streptomycin to
the ribosomal S12 protein and 16S rRNA gene
(Douglass & Steyn, 1993; Nair et al., 1993).
Recent work has identified mutations in a gene
possibly involved in the mycolic acid metabolic
pathway as an additional mechanism for
isoniazid resistance in M. tuberculosis
(Banerjee et al., 1993).
We have evaluated the rpoB of several
strains of M. avium and Mycobacterium intra-
cellulare that displayed variable levels of
susceptibility to rifampicin to clarify its role in
resistance. For this purpose, the rpoB region
where mutations have been identified in
M. tuberculosis and Mycobacterium leprae
(Honore & Cole, 1993; Telenti et al.,
1993a)—the Rif locus—was amplified in
M. avium serovar 1, and M. intracellulare
serovar 15 reference strains by using primers
previously described (Telenti et al., 1993a).
PCR fragments were sequenced directly or
after cloning into a plasmid vector. In addi-
tion, the Rif locus was evaluated in 29 human
MAC isolates displaying a rifampicin-suscept-
ible phenotype (MIC < 1 mg/L, n = 4),
moderate susceptibility (MIC 1-4 mg/L, n =
6), or resistance (MIC £ 4 mg/L, n = 19), by
sequencing or by PCR single strand conforma-
tion polymorphism (Telenti et al., 19936).
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Tabfe. Alignment of the rpoB Rif locus of rifampicin susceptible M. tuberculosis H37rv with sequences from M. avium and M. intracellulare reference strains and 15
clinical isolates (grouped as 'types' according to sequence homology) exhibiting susceptible, intermediate resistant, and rifampicin resistant phenotypes. With the
exception of the M. intracellulare isolate 'D', all isolates had full amino acid homology with M. tuberculosis H37rv. Shown in bold are the mutations described in
rifampicin-resistant M. tuberculosis
M. tuberculosis AAC ATC CGG CCG GTG GTC GCC GCG ATC AAG GAG TTC TTC GGC ACC AGC CAG CTG AGC CAA TCC ATG GAC CAG
494 Asn He Arg Pro Val Val Ala Ala He Lys Glu Phe Phc Gly Thr Ser Gin U u Ser Gin Phe Met Asp Gin
M. avium AAC ATC CGT CCC GTC GTG GCG GCG ATC AAG GAG TTC TTC GGC ACC AGC CAG CTG TCC CAG TTC ATG GAC CAG
type A (n = 3)
type B (n - 4) A
type C ( n - I ) C C
M. intracellulare . . . . G .G .. . . C . C AG
type A (n •= I) G . . G .. . . C . . C AG
type B (n = 3) G .. G C .. C G
type C(n = 2) G . . G C . C G
typeD(/r=l) G G ..G C ..C AG
Ser
M. tuberculosis AAC AAC CCG CTG TCG GGG TTG ACC CAC AAG CGC CGA CTG TCG GCG CTG GGG CCC GGC GGT CTG TCA CGT GAG
518 Asn Asn Pro Leu Ser Gly Leu Thr Hb Lys Arg Arg Leu Ser Ala Leo Gly Pro Gly Gly Leu Ser Arg Glu
M. avium AAC AAC CCG CTG TCG GGG CTC ACC CAC AAG CGC CGC CTG TCG GCG CTG GGC CCG GGT GGT CTG TCC CGG GAG
type A (n = 3)
type B (/. = 4)
type C (rt= I) T . . G T . . .
M. inlracellulare C .T ..G C C ..C T ...
typeA(n=l) C ..T .G C C ,.C T ...
typeB(n = 3) C . T ,.G C C . C T ...
typeC(n = 2) C .. ..G T ..T . C C T . .
type D ( n = l ) G T .. T G ..C T ...
n
o
•g
3.
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In M. avium and M. intracellulare reference
strains, the rpoB region homologous to the Rif
locus of M. tuberculosis exhibited differences
at nucleotide level but a full amino acid iden-
tity with rifampicin-susceptible M. tuberculosis
(Table). Sequence information from clinical
isolates demonstrated significant sequence
heterogeneity, in particular among strains
identified as M. intracellulare. However, with
only one exception, all retained the amino acid
sequence corresponding to a rifampicin-
susceptible M. tuberculosis (Table). One isolate
presented an Asn -> Ser in codon 494, a
mutation not reported previously in rifam-
picin-resistant M. tuberculosis (Telenti et al.,
1993a), or M. leprae (Honore & Cole, 1992).
This isolate did not display high level
resistance—it had no growth at 4 mg/L of
rifampicin; thus, the contribution of the
mutation to the resistant phenotype was
deemed doubtful.
In summary, our data confirm at the
molecular level that the most frequent mechan-
ism of resistance to nfampicin among clinical
isolates of M. avium and M. intracellulare does
not involve alterations of the RNA polymerase
subunit /?. Thus, alternative mechanisms of
resistance are responsible for the intrinsic
resistance to rifampicin in MAC. The
frequency with which these isolates exhibit
resistance to multiple structurally unrelated
antimicrobial agents, and the existence of
intermediate and high-level resistance pheno-
types are most consistent with changes in drug
uptake or with efflux mechanisms. A signifi-
cant permeability barrier to rifampicin, that
could be reduced with Tween, has been
described in a type strain of M. intracellulare
and Mycobacterium smegmatis shown to
possess a rifampicin-susceptible RNA poly-
merase (Hui, Gordon & Kajioka, 1977). The
genetic determinants of permeability, and the
possibility for additional mechanisms of resist-
ance to antimicrobial agents in MAC,
including the acquisition of exogenous genetic
elements encoding for drug resistance, have
not yet been established. This information will
be important in the development of more
active drugs against MAC.
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Outer membrane protein profiles of
Xanthomonas maltophilia isolates displaying
temperature-dependent susceptibility to
genUmicin
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Sir,
Xanthomonas maltophilia is increasingly
isolated from hospitalized patients, parti-
cularly immunocompromised individuals
receiving broad-spectrum antibiotics.
Treatment is difficult because of its inherent
resistance to many antibiotics. Wheat,
